메소블라스트(MESO)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $15.05 (+1.21%), 시가총액 $1.92B, 52주 최저~최고 $10.16 ~ $20.96.
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain
메소블라스트의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
메소블라스트의 현재 주가는 $15.05 (+1.21%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
메소블라스트의 시가총액은 약 $1.92B입니다.
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary r